SINOVA-M-14042 D-Dimer Quantitative Test Kit

Clinical Significance: D-Dimer primarily reflects fibrinolytic activity. Elevated or positive levels are observed in secondary hyperfibrinolysis conditions such as hypercoagulable states, disseminated intravascular coagulation (DIC), kidney diseases, organ transplant rejection, thrombolytic therapy, and other conditions. Whenever there is active thrombus formation and fibrinolytic activity within the body's vasculature, D-Dimer levels will rise. Elevated levels can be found in myocardial infarction, cerebral infarction, pulmonary embolism, venous thrombosis, surgery, tumors, DIC, infections, and tissue necrosis. Particularly in elderly and hospitalized patients, conditions like bacteremia can lead to coagulation abnormalities and elevated D-Dimer levels.
Product Specifications: 20 tests/box
Product Shelf Life: 18 months when sealed in an aluminum foil pouch. Use within 1 hour after opening the pouch.
Product Storage: Store the test card at 2℃-30℃.
 
Usage Scenarios:
Hospitals and Clinics: For diagnosing and monitoring conditions associated with hyperfibrinolysis, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC).
Cardiology and Neurology Departments: For assessing thrombotic events in myocardial infarction and cerebral infarction.
Surgery and Intensive Care Units (ICUs): For monitoring post-operative patients and those undergoing thrombolytic therapy.
Diagnostic Laboratories: For routine testing of D-Dimer levels to evaluate thrombotic activity and fibrinolysis.
Suitable Countries and Regions:
Developed Countries: United States, Canada, Western Europe (e.g., Germany, France, UK), Japan, Australia, etc., where advanced diagnostic tools are widely used for managing thrombotic and fibrinolytic disorders.
Emerging Markets: China, India, Southeast Asia, Latin America, Eastern Europe, Middle East, etc., where healthcare systems are expanding diagnostic capabilities for thrombotic conditions.
Global Health Programs: International health initiatives focused on improving the diagnosis and management of thrombotic and fibrinolytic disorders in low-resource settings.